AN2 Therapeutics, Inc.
ANTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,000 | $3,200 | $7,690 | $5,397 |
| G&A Expenses | $3,040 | $4,016 | $3,847 | $3,210 |
| SG&A Expenses | $3,040 | $4,016 | $3,847 | $3,210 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$9 |
| Operating Expenses | $10,040 | $7,216 | $11,537 | $8,598 |
| Operating Income | -$10,040 | -$7,216 | -$11,537 | -$8,598 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $687 | $754 | $888 | $1,076 |
| Pre-Tax Income | -$9,353 | -$6,462 | -$10,649 | -$7,522 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9,353 | -$6,462 | -$10,649 | -$7,522 |
| % Margin | – | – | – | – |
| EPS | -0.31 | -0.21 | -0.35 | -0.25 |
| % Growth | -47.6% | 40% | -40% | – |
| EPS Diluted | -0.31 | -0.21 | -0.35 | -0.25 |
| Weighted Avg Shares Out | 30,276 | 30,172 | 30,054 | 29,883 |
| Weighted Avg Shares Out Dil | 30,276 | 30,172 | 30,054 | 29,883 |
| Supplemental Information | – | – | – | – |
| Interest Income | $687 | $754 | $888 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $8,607 |
| EBITDA | -$9,353 | -$7,216 | -$11,537 | $0 |
| % Margin | – | – | – | – |